|
Re: Coronavirus
I'm not sure how, in a pandemic, a regulator is supposed to isolate supply from their decision making. The whole point is surely to reduce both prevalence and transmission across the population. A drug where supplies are unable to significantly do either must factor into whether the benefits outweigh the risks because the benefits and risks are intrinsically linked to what non-pharmaceutical are required.
As for politicians and regulators my cynicism knows no geographic bounds.
|